JCR Pharmaceuticals
As of the edition of 20 October 2026, JCR Pharmaceuticals runs 8 drugs, 5 of them marketed; it is on route A at 0 targets and on route B at 4 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 5 |
| Active | 2 |
| Status not established | 1 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Somatropin | Ended 2003 (orphan exclusivity) | 4 |
| Darbepoetin alfa | Ended 2013 (computed from the first US licence) | 1 |
| Agalsidase beta | Ends 2028 (orphan exclusivity) | 0 |
| Pabinafusp alfa | none listed | 2 |
| Epoetin kappa | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 4 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where JCR Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Inherited and neonatal: 11 trials led
- Nutrition and metabolism: 11 trials led
- Skin and connective tissue: 11 trials led